Daniel Reed brings a background in healthcare finance and more than a decade of experience building pharmaceutical businesses. His work includes leading drug-development programs through FDA approval and contributing as a named inventor on multiple therapeutic patents.
At GLP1 Rank, Daniel examines clinical research, treatment access, and the business practices behind online weight-management services. His coverage focuses on helping readers understand the evidence, compare complete costs, and recognize important differences between provider offers.
What informs the coverage
Pharmaceutical development provides a perspective on how research becomes a treatment claim. Healthcare finance adds a practical lens for examining fees, incentives and business models. These perspectives inform the questions GLP1 Rank asks of studies and provider offers.
Editorial scope
Daniel is not a licensed clinician. GLP1 Rank publishes educational research and service comparisons, not individualized medical advice. Articles identify their sources and limitations; an author byline does not imply medical review or firsthand treatment experience.
Read our editorial standards and how affiliate relationships support the publication.
Explore the research
- How to read GLP-1 research without overreading a headline
- Tirzepatide vs semaglutide: what SURMOUNT-5 actually found
- Weight regain after stopping GLP-1 treatment: what two studies show
- GLP-1 weight-loss plateaus: what the trial timelines mean